A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.

Enrolled patients will receive upfront (week 1) short-course radiotherapy to gross pelvic disease (25Gy in 5fx) in combination with AB928 (150 mg orally, once daily as part of a continuous dose regimen). This will be followed by consolidation chemotherapy (weeks 3-20) with mFOLFOX x9 cycles in combination with AB928 and AB122.

Trial Details

NCT ID
NCT05024097
Phase
PHASE2
Sponsor
Weill Medical College of Cornell University
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Etrumadenant (AB928)
  • Radiation therapy
  • FOLFOX regimen
  • Zimberelimab (AB122)
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597
  • New York, New York, United States|40.71427,-74.00597
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Histologically confirmed diagnosis of adenocarcinoma of the rectum
  • Age ≥ 18 years
  • ECOG performance status 0-1
  • cT3N0 or cT1-3N1 or cT4 or cN2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →